Wen-Zhao Zhong,Ke-Neng Chen,Chun Chen,Chun-Dong Gu,Jun Wang,Xue-Ning Yang,Wei-Min Mao,Qun Wang,Gui-Bin Qiao,Ying Cheng,Lin Xu,Chang-Li Wang,Ming-Wei Chen,Xiaozheng Kang,Wanpu Yan,Hong-Hong Yan,Ri-Qiang Liao,Jin-Ji Yang,Xu-Chao Zhang,Qing Zhou,Yi-Long Wu

Abstract:PURPOSETo assess the benefits of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as neoadjuvant/adjuvant therapies in locally advanced EGFR mutation-positive non–small-cell lung cancer.PATIENTS AND METHODSThis was a multicenter (17 centers in China), open-label, phase II, randomized controlled trial of erlotinib versus gemcitabine plus cisplatin (GC chemotherapy) as neoadjuvant/adjuvant therapy in patients with stage IIIA-N2 non–small-cell lung cancer with EGFR mutations in exon 19 or 21 (EMERGING). Patients received erlotinib 150 mg/d (neoadjuvant therapy, 42 days; adjuvant therapy, up to 12 months) or gemcitabine 1,250 mg/m2 plus cisplatin 75 mg/m2 (neoadjuvant therapy, two cycles; adjuvant therapy, up to two cycles). Assessments were performed at 6 weeks and every 3 months postsurgery. The primary end point was objective response rate (ORR) by Response …

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA N2 EGFR Mutant Non–Small Cell Lung Cancer (EMERGING CTONG 1103): A …